Doxorubicin-peptide conjugates overcome multidrug resistance

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Multidrug resistance (MDR) in cancer is often mediated by P-glycoprotein (P-gp) efflux pumps.
• P-gp overexpression reduces intracellular drug accumulation, limiting chemotherapy effectiveness.
• Novel drug delivery strategies are needed to overcome P-gp-mediated resistance.

Purpose of the Study:

• To evaluate peptide vectors for delivering doxorubicin into P-gp-expressing multidrug-resistant cells.
• To assess the efficacy of peptide-conjugated doxorubicin against resistant cancer cells.
• To determine if the peptide-drug conjugate bypasses P-gp efflux mechanisms.

Main Methods:

• Utilized peptide vectors capable of cellular membrane crossing.
• Tested peptide-doxorubicin conjugates in human erythroleukemic K562/ADR cells.
• Assessed cytotoxicity and intracellular drug levels with and without verapamil.
• Employed in situ brain perfusion in mice to evaluate blood-brain barrier penetration.

Main Results:

• Peptide-conjugated doxorubicin demonstrated potent, dose-dependent inhibition of K562/ADR cell growth.
• Vectorized doxorubicin showed significantly lower IC50 values (3 microM) compared to free doxorubicin (65 microM).
• The conjugate's efficacy was unaffected by verapamil, indicating P-gp bypass.
• Vectorized doxorubicin successfully bypassed P-gp at the blood-brain barrier in mice.

Conclusions:

• Peptide vectorization is an effective strategy to overcome P-gp-mediated multidrug resistance.
• Doxorubicin conjugation with peptide vectors enhances its delivery and efficacy in resistant cancer cells.
• This approach shows potential for improving chemotherapy outcomes in MDR cancers, including brain tumors.